Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DSM and Chemtrix Sign Collaboration Agreement

Published: Friday, February 22, 2013
Last Updated: Thursday, February 21, 2013
Bookmark and Share
DSM to provide sustainable equipment and, development and manufacturing services to the pharmaceutical industry.

DSM Pharmaceutical Products has announced that it has signed a collaboration agreement with Chemtrix B.V., The Netherlands, in the field of Continuous Flow Chemistry to provide sustainable equipment and, development and manufacturing services to the pharmaceutical industry.

The agreement brings together the expertise of both parties in continuous flow chemistry to better serve the pharmaceutical industry with processes for the development and manufacture of active pharmaceutical ingredients (APIs), which require new technologies to increase sustainability, reduce energy consumption and provide benefits for cost-of-goods.

Chemtrix’ specializes in ready-to-use laboratory and kilo-scale micro reactors, as well as reactor and process design for industrial reactors, which complement DSM’s proven track record in drug synthesis route development, scale-up and implementation of continuous flow processes for manufacturing.

DSM achieved one of the first industrial scale, FDA approved uses of micro reactors for making a pharmaceutical at commercial scale under current Good Manufacturing Practices (cGMP) at their facility in Linz, Austria.

Initially the DSM-Chemtrix collaboration will offer an Industrial Flow Process Development package to clients, in order to provide tailor-made, scalable flow chemistry solutions.

This package covers all phases of process design, from scanning chemistries, chemistry development, route scouting, equipment design and scale-up for fully continuous or integrated processes.

Alexander Wessels, President and CEO of DSM Pharmaceutical Products, stated, "Working with Chemtrix underlines the further advancement of DSM's stated strategy toward strategic partnerships to excel in providing new customer solutions. DSM is a global leader in cGMP continuous flow chemistry manufacturing, with a commitment to the future of pharmaceutical manufacturing in a sustainable manner."

Simon Hickling Ph.D., Senior Business Manager at DSM, added, “Continuous flow chemistries are becoming more important in API manufacturing, as the pharmaceutical industry focuses on sustainable manufacturing solutions and competitive cost-of-goods. Together with Chemtrix we now offer a complete turnkey solution to manufacturing in flow-reactors from conception to cGMP bulk manufacturing; flow chemistry to the power of two.”

Hugo Delissen, CEO of Chemtrix BV, stated, “Together with DSM we are the most complete flow chemistry partner for pharmaceutical and fine chemical companies. Delivering a complete package of equipment and services based on our joint knowledge ranging from lab (milligrams) to production (ton) scale, ensures the delivery of the best possible solutions for our joint customers.”

“With this collaboration we complete our product portfolio which has always been based on scalability. Using micro reactors for flow chemistry method development is only valuable if customers can use it to produce their products on commercial scale. To ensure that the whole scale-up process will run smoothly together we offer a complete service package which will help our customers to implement this process intensification technology to improve the sustainability and safety of their processes.”, added Dr. Charlotte Wiles, Chief Technology Officer of Chemtrix BV.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!